AI-powered medicinal research company Iktos and private global pharmaceutical company Italfarmaco have announced a collaboration to develop next-generation histone deacetylase (HDAC) inhibitors for a range of diseases, including those affecting the central nervous system. The terms and financial details of the agreement have not been disclosed.
The partnership aims to develop HDAC inhibitors using Iktos' AI-powered drug discovery platforms, Makya and Spaya. Italfarmaco will leverage its experience in epigenetics and HDAC inhibitors and Iktos' AI expertise to identify promising drug candidates faster and more efficiently.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.